VivoSeq
Hematology

Porphyria Cutanea Tarda

4

Pipeline Programs↗

0

Active Trials↗

3

Companies Involved↗

Porphyria Cutanea Tarda is an early-stage landscape with 4 programs across 3 companies. The most active players are Alnylam Pharmaceuticals, Gilead, Novartis. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 2Gilead logo

Gilead

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

4

clinical trials

Completed3 · 75%
Unknown status1 · 25%

Clinical Trials

Trial Activity

Harvoni Treatment Porphyria Cutanea Tarda
Completed·WWake Forest University Health Sciences·Phase 2·NCT03118674·23 enrolled
Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda
Completed·TThe University of Texas Medical Branch, Galveston·Phase 2·NCT01573754·48 enrolled
Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda
Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT01284946·45 enrolled
Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda
Completed·UUniversity of Texas Southwestern Medical Center·Phase 3·NCT00599326·10 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)